For anyone in Dausa looking to source CJC-1295, the key fact to understand is that this compound moves through online research channels. This online-only market structure is ultimately a quality advantage — top vendors differentiate through analytical documentation in ways local stores never could. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. This guide walks Dausa researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Dausa comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy CJC-1295 — A Researcher's Guide
Assessing CJC-1295 vendors requires starting from the COA: access the batch-specific certificate before placing an order, not after. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. Community reputation in research forums is a complementary signal to COA verification — vendors with sustained positive community feedback have built their reputation on real product performance. Bacteriostatic water is the standard reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to approximately one month when stored at 2-8°C.
Order CJC-1295 — ships to Dausa
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human consumption by the FDA or comparable health authorities — all information here is educational. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; do not freeze and thaw reconstituted CJC-1295 multiple times by preparing small aliquots before storage. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no cost saving makes omitting this acceptable. Protocol documentation — documenting product details, dates, and administration precisely — is a fundamental research principle that ensures unusual findings can be explained.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
